$2 by weeks end, page-6

There is alot more to it than that.. importing and selling another companies product isn't where the money is at.. they are planning on building their own facilties to be able to cultivate and manufacture themselves (year away minimum). However for althea to be along side ac8 and can, they need to achieve alot more. For starters, the oils they are importing from aphria are useless for the Australian medical world as it isnt in a stable final dose form. They need to come up with a way to stop the degradation of the compounds whilst on the shelf like auscann have done over the last 10 months. Otherwise for example their THC oil will turn to CBN oil whilst in storage, which cant happen when we are talking about medicines. Not only do they need to figure all that out but they also need to put together their own unique formulas for specific conditions and patent them. They are only currently importing standard thc/cbc blends with differing ratios.. same as many other companies. Once they come up with their own unique formulas they will need to patent them (currently they have 0 Australian patents) and more importantly, put them through clinical trials. There is alot for them to do to be on par with the other 2. It would also be nice to have some good detail on what ailments althea are targeting. Ie) auscann have made it clear their market is chronic and neuropathic pain.

I am very tempted to buy althea because of their tight register, 25% aphria holding and the possibility of another CAN run, however i think their fundamentals arent quite the same.. CANs government links and the fact they are selling their buds to the VIC government put them well above althea at the moment. Not to mention CAN being the first company to receive a licence. Its a hard one... im definetly buying.. but to buy now or buy later that is the question